☰

Debabrita Deb, Ph.D. - Publications

Affiliations: 
2001 Wake Forest University School of Medicine, Winston-Salem, NC, United States 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2008 Scian MJ, Carchman EH, Mohanraj L, Stagliano KE, Anderson MA, Deb D, Crane BM, Kiyono T, Windle B, Deb SP, Deb S. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene. 27: 2583-93. PMID 17982488 DOI: 10.1038/Sj.Onc.1210898  0.744
2004 Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K, Deb SP, Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene. 23: 4430-43. PMID 15077194 DOI: 10.1038/Sj.Onc.1207553  0.742
2002 Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. The Journal of Biological Chemistry. 277: 44988-95. PMID 12239215 DOI: 10.1074/Jbc.M207176200  0.419
2002 Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, Mohindru M, Van Besien K, Platanias LC. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. Journal of Immunology (Baltimore, Md. : 1950). 168: 5984-8. PMID 12055203 DOI: 10.4049/Jimmunol.168.12.5984  0.316
2002 Mahmud DL, G-Amlak M, Deb DK, Platanias LC, Uddin S, Wickrema A. Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene. 21: 1556-62. PMID 11896584 DOI: 10.1038/Sj.Onc.1205230  0.339
2002 Deb D, Scian M, Roth KE, Li W, Keiger J, Chakraborti AS, Deb SP, Deb S. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants. Oncogene. 21: 176-89. PMID 11803461 DOI: 10.1038/sj.onc.1205035  0.765
2002 Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, Platanias LC. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. The Journal of Biological Chemistry. 277: 7726-35. PMID 11773065 DOI: 10.1074/Jbc.M106640200  0.419
2001 Brown DR, Deb D, Frum R, Hickes L, Munoz R, Deb S, Deb SP. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants. International Journal of Oncology. 18: 449-59. PMID 11179471 DOI: 10.3892/Ijo.18.3.449  0.747
2001 Deb D, Lanyi A, Scian M, Keiger J, Brown DR, Le Roith D, Deb SP, Deb S. Differential modulation of cellular and viral promoters by p73 and p53. International Journal of Oncology. 18: 401-9. PMID 11172610 DOI: 10.3892/Ijo.18.2.401  0.741
1999 Deb D, Chakraborti AS, Lányi A, Troyer DA, Deb S. Disruption of functions of wild-type p53 by hetero-oligomerization. International Journal of Oncology. 15: 413-22. PMID 10427119  0.761
1998 Lányi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene. 16: 3169-76. PMID 9671396 DOI: 10.1038/sj.onc.1201857  0.748
Show low-probability matches.